# A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

> **NCT04602624** · PHASE2 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Alzheimer Disease
- Cognitive Dysfunction
- Mild Dementia

## Interventions

- **DRUG:** SAGE-718

## Key facts

- **NCT ID:** NCT04602624
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-07
- **Primary completion:** 2021-09-28
- **Final completion:** 2021-09-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04602624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04602624, "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04602624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*